Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antimicrob Agents Chemother
    September 2022
  1. LUTERBACH CL, Qiu H, Hanafin PO, Sharma R, et al
    A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Antimicrob Agents Chemother. 2022 Sep 20:e0059122. doi: 10.1128/aac.00591.
    >> Share

  2. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
    Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
    >> Share

    August 2022
  3. PHAM MM, Podany AT, Mwelase N, Supparatpinyo K, et al
    Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrob Agents Chemother. 2022 Aug 9:e0238521. doi: 10.1128/aac.02385.
    >> Share

    July 2022
  4. DEVANATHAN AS, White NR, Desyaterik Y, De la Cruz G, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.
    Antimicrob Agents Chemother. 2022 Jul 20:e0060922. doi: 10.1128/aac.00609.
    >> Share

  5. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    >> Share

    May 2022
  6. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
    Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
    >> Share

  7. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    >> Share

  8. DIAMOND TL, Ngo W, Xu M, Goh SL, et al
    Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Antimicrob Agents Chemother. 2022 May 12:e0013322. doi: 10.1128/aac.00133.
    >> Share

  9. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    >> Share

  10. GARTLAND M, Cahn P, DeJesus E, Diaz RS, et al
    Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Antimicrob Agents Chemother. 2022 May 3:e0175121. doi: 10.1128/aac.01751.
    >> Share

  11. LAI MT, Feng M, Xu M, Ngo W, et al
    Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022 May 2:e0222321. doi: 10.1128/aac.02223.
    >> Share

    April 2022
  12. ACOSTA RK, D'Antoni ML, Mulato A, Yant SR, et al
    Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
    Antimicrob Agents Chemother. 2022 Apr 7:e0203821. doi: 10.1128/aac.02038.
    >> Share

    March 2022
  13. SONG N, Zhou X, Li D, Li X, et al
    A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.
    Antimicrob Agents Chemother. 2022 Mar 28:e0210521. doi: 10.1128/aac.02105.
    >> Share

  14. MOORE K, Thakkar N, Magee M, Sevinsky H, et al
    Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Antimicrob Agents Chemother. 2022 Mar 22:e0225121. doi: 10.1128/aac.02251.
    >> Share

  15. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    >> Share

  16. WALLACE J, Gonzalez H, Rajan R, Narasipura SD, et al
    Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
    Antimicrob Agents Chemother. 2022 Mar 16:e0194121. doi: 10.1128/aac.01941.
    >> Share

  17. MWANGI JN, Gilliland WM Jr, White N, Sykes C, et al
    Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Antimicrob Agents Chemother. 2022 Mar 10:e0217621. doi: 10.1128/aac.02176.
    >> Share

    February 2022
  18. HAN K, Wannamaker P, Lu H, Zhu B, et al
    Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Antimicrob Agents Chemother. 2022 Feb 7:AAC0205721. doi: 10.1128/AAC.02057.
    >> Share

    January 2022
  19. JEFFREY JL, St Clair M, Wang P, Wang C, et al
    Impact of Integrase Sequences From HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0170221. doi: 10.1128/AAC.01702.
    >> Share

  20. AMANO M, Yedidi RS, Salcedo-Gomez PM, Hayashi H, et al
    Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors In Vitro.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0171521. doi: 10.1128/AAC.01715.
    >> Share

    December 2021
  21. LAI PC, Chen CH, Jeng LB, Yu TM, et al
    Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0200321. doi: 10.1128/AAC.02003.
    >> Share

  22. AGUIAR-ALVES F, Le HN, Tran VG, Gras E, et al
    Anti-virulence Bispecific Monoclonal Antibody Mediated Protection Against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0202221. doi: 10.1128/AAC.02022.
    >> Share

  23. LOMBAARD J, Ssali F, Thanyawee P, Fourie J, et al
    Long-term safety, tolerability and antiviral activity of rilpivirine in antiretroviral-naive adolescents living with HIV-1, aged 12 to less than 18 years: Week 240 findings of a phase 2, open-label study, PAINT.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0091621. doi: 10.1128/AAC.00916.
    >> Share

    November 2021
  24. POON R, Basuino L, Satishkumar N, Chatterjee A, et al
    Loss of GdpP function in Staphylococcus aureus leads to beta-lactam tolerance and enhanced evolution of beta-lactam resistance.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0143121. doi: 10.1128/AAC.01431.
    >> Share

  25. DICKER I, Jeffrey JL, Protack T, Lin Z, et al
    GSK3640254 Is a Novel HIV-1 Maturation Inhibitor With an Optimized Virology Profile.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0187621. doi: 10.1128/AAC.01876.
    >> Share

  26. ZHANG CX, Love MS, McNamara CW, Chi V, et al
    Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis.
    Antimicrob Agents Chemother. 2021 Nov 8:AAC0156021. doi: 10.1128/AAC.01560.
    >> Share

  27. BOYER PL, Rehm CA, Sneller MC, Mican J, et al
    A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0150021. doi: 10.1128/AAC.01500.
    >> Share

    October 2021
  28. VAVRO C, Ruel T, Wiznia A, Montanez N, et al
    Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164521. doi: 10.1128/AAC.01645.
    >> Share

  29. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the D
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164321. doi: 10.1128/AAC.01643.
    >> Share

  30. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Mutations in the HIV-1 3'-polypurine tract can confer dolutegravir resistance.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0102721. doi: 10.1128/AAC.01027.
    >> Share

    September 2021
  31. ASANTE-APPIAH E, Lai J, Wan H, Yang D, et al
    Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0121621. doi: 10.1128/AAC.01216.
    >> Share

  32. ABDELWAHAB MT, Wasserman S, Brust JCM, Dheda K, et al
    Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0138121. doi: 10.1128/AAC.01381.
    >> Share

  33. ANKROM W, Jackson Rudd D, Schaeffer A, Panebianco D, et al
    Pharmacokinetic and Safety Profile of the Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0093521. doi: 10.1128/AAC.00935.
    >> Share

  34. CILENTO ME, Reeve AB, Michailidis E, Ilina TV, et al
    Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0116721. doi: 10.1128/AAC.01167.
    >> Share

  35. ZHOU CL, Huang YF, Li YB, Liang TZ, et al
    A new small-molecule compound, Q308, silences latent HIV-1 provirus by suppressing Tat- and FACT-mediated transcription.
    Antimicrob Agents Chemother. 2021 Sep 7:AAC0047021. doi: 10.1128/AAC.00470.
    >> Share

    August 2021
  36. SALAAM-DREYER Z, Streicher EM, Sirgel FA, Menardo F, et al
    Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0036421. doi: 10.1128/AAC.00364.
    >> Share

  37. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    >> Share

  38. KULARATNE RS, Kufa T, Gumede L, Maseko DV, et al
    Demographic and behavioural risk factors associated with reduced susceptibility of Neisseria gonorrhoeae to first-line antimicrobials in South African men with gonococcal urethral discharge.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0038921. doi: 10.1128/AAC.00389.
    >> Share

    July 2021
  39. CHIA T, Nakamura T, Amano M, Takamune N, et al
    A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid.
    Antimicrob Agents Chemother. 2021 Jul 6:AAC0103921. doi: 10.1128/AAC.01039.
    >> Share

    June 2021
  40. KA S, Merindol N, Sow AA, Singh A, et al
    Amaryllidaceae alkaloid cherylline inhibits the replication of dengue and Zika viruses.
    Antimicrob Agents Chemother. 2021 Jun 21:AAC0039821. doi: 10.1128/AAC.00398.
    >> Share

    May 2021
  41. WASSERMAN S, Davis A, Stek C, Chirehwa M, et al
    Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00140.
    >> Share

  42. NGUYEN NTQ, Gras E, Tran ND, Nguyen NNY, et al
    Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.02724.
    >> Share

    April 2021
  43. MAO Y, Valour F, Nguyen NTQ, Doan TMN, et al
    Multi-mechanistic Monoclonal Antibody Combination Targeting Key Staphylococcus aureus Virulence Determinants in a Rabbit Model of Prosthetic Joint Infection.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.01832.
    >> Share

  44. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    >> Share

    March 2021
  45. SCHOLZ EMB, Mwangi JN, De la Cruz G, Nekorchuk M, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, RT-SHIV RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.00019.
    >> Share

  46. PENE DUMITRESCU T, Joshi SR, Xu J, Zhan J, et al
    A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Antimicrob Agents Chemother. 2021 Mar 22. pii: AAC.02173.
    >> Share

  47. WEI Y, Sluis-Cremer N
    Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand-Transfer Inhibitor Resistance.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02432.
    >> Share

  48. WHITE KL, Osman N, Cuadra-Foy E, Brenner BG, et al
    Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.02406.
    >> Share

    February 2021
  49. BRUGGEMANS A, Vansant G, Balakrishnan M, Mitchell ML, et al
    GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02328.
    >> Share

  50. LODISE TP, Van Wart S, Sund ZM, Bressler AM, et al
    Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  51. MANDAL S, Prathipati PK, Sunagawa SW, Destache CJ, et al
    A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02320.
    >> Share

    December 2020
  52. FERNANDEZ ML, Marson ME, Mastrantonio GE, Corti MA, et al
    BENZNIDAZOLE IN CEREBROSPINAL FLUID. A CASE SERIES OF CHAGAS DISEASE MENINGOENCEPHALITIS IN HIV POSITIVE PATIENTS.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.01922.
    >> Share

  53. EKE AC, Shoji K, Best BM, Momper JD, et al
    Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women using Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2020 Dec 14. pii: AAC.02168.
    >> Share

  54. MARGOT N, Ram R, Rhee M, Callebaut C, et al
    Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.02057.
    >> Share

    November 2020
  55. KANE A, Campbell L, Ky D, Hibbs D, et al
    The antifungal and synergistic effect of bisphosphonates in Cryptococcus.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01753.
    >> Share

  56. PHAM CD, Nash E, Liu H, Schmerer MW, et al
    Atypical Mutation in Neisseria gonorrhoeae 23S rRNA Associated with High-Level Azithromycin Resistance.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00885.
    >> Share

  57. ZUTZ A, Chen L, Sippl F, Humpe A, et al
    Epigenetic compound screening uncovers small molecules for re-activation of latent HIV-1.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01815.
    >> Share

    October 2020
  58. CALCAGNO A, Dal Conte I, Cattaneo D, Testi R, et al
    Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01902.
    >> Share

  59. WILLBY M, Chopra P, Lemmer D, Klein K, et al
    Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
    >> Share

  60. BYRNE JM, Waack U, Weinstein EA, Joshi A, et al
    FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01983.
    >> Share

  61. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    >> Share

  62. BARBEE LA, Soge OO, Ocbamichael N, LeClair A, et al
    A Single-arm Open-label Clinical Trial of 2g Aztreonam for the treatment of N. gonorrhoeae.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01739.
    >> Share

  63. ELDESOUKY HE, Salama EA, Lanman NA, Hazbun TR, et al
    Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00684.
    >> Share

  64. BOWMAN ER, Cameron C, Richardson B, Kulkarni M, et al
    In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01755.
    >> Share

  65. HUGHES E, Imperial M, Wallender E, Kajubi R, et al
    Piperaquine exposure is altered by pregnancy, HIV and nutritional status in Ugandan women.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01013.
    >> Share

  66. BENAMOR TEIXEIRA ML, Fuller TL, Fragoso da Silveira Gouvea MI, Santos Cruz ML, et al
    Efficacy of Three Antiretroviral Regimens Initiated during Pregnancy: Clinical Experience in Rio de Janeiro.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01068.
    >> Share

    June 2020
  67. PARSONS TL, Gwenden KN, Marzinke MA
    Inter-species Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00930.
    >> Share

    February 2020
  68. EKE AC, Wang J, Amin K, Shapiro DE, et al
    Fosamprenavir with Ritonavir Pharmacokinetics During Pregnancy.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02260.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016